Partner Marc Ross Represents Israeli Medical Marijuana Company OWC Pharmaceutical Research Corp. in Financing
Press Release – New York, NY – December 30, 2015 – Securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the firm has represented OWC Pharmaceutical Research Corp. (OTCQB: OWCP) (the “Company”), a company focused on discovering, developing and commercializing cannabis-based novel therapeutics and treatments, in connection with a $37,500 convertible note and $750,000 equity purchase agreement with Kodiak Capital Group, LLC., a California-based institutional investor (“Kodiak”). The Company has agreed to file a registration statement with the SEC covering the shares issuable upon conversion of the note and the shares that may be issued to Kodiak under the terms of the agreement. After the SEC has declared the registration statement related to the transaction effective, the Company will have the right at its sole discretion to sell up to $750,000 of common stock under the terms set forth in the agreement. The Sichenzia Ross Friedman Ference LLP team was led by partners Marc Ross and James Turner and associate Avital Even-Shoshan.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Founding Partner Gregory Sichenzia Featured in Business Insider Discussing the Legal Aftermath for Tesla - September 19, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for AusCann Group Holdings Ltd on OTCQX Listing - September 15, 2018
- Sichenzia Ross Ference LLP Acts as Principal Attorney Liaison for Zelda Therapeutics Ltd on OTCQX Listing - September 15, 2018